The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

The pharmaceutical company AstraZeneca has completed the transition to a fully electric vehicle fleet in Switzerland. All of ...

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Morgan Stanley同样对AstraZeneca表示信心，给予增持评级和GBP145.00的目标价。该机构预计公司收入和每股收益将实现增长。Goldman Sachs虽然将AstraZeneca的目标价下调至GBP150.67，但重申买入评级，理由是公司拥有强大的产品管线，且中国市场的挑战可控。

Beijing appears to be extending an olive branch to the previously under-fire drug maker as it tries to shore up private ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...